The Shanghai Stock Exchange announced on its website that the review of Beijing Huahao Zhongtian Biopharmaceutical Co., Ltd.'s IPO application has been terminated due to the company and its underwriter withdrawing the application. According to Article 63 of the Shanghai Stock Exchange's Stock Issuance and Listing Review Rules, the exchange is required to terminate the review. It was reported that the Shanghai Stock Exchange accepted the company's IPO application for the STAR Market in June 2022.